ClinicalTrials.gg
RecruitingNCT07890558Updated Oct 22, 2026

Addressing Spasticity and Motor Function With Epidural Spinal Cord Stimulation

An interventional study of Epidural implant stimulation device in SCI - Spinal Cord Injury and Spasticity, sponsored by Kessler Foundation. Recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Kessler Foundation · Not applicable, Interventional, and Treatment

Updated Oct 22, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate treating severe spasticity in persons with spinal cord injury by implanting a device in the body that delivers electrical stimulation around the spinal cord (spinal cord epidural stimulation). This study will be closely monitoring a program designed to treat spasticity using an epidural stimulator to better understand its effects on spasticity and voluntary movement.

Read the detailed description

This study aims to expand our knowledge and capacity for neuromodulation to improve the debilitating effects of severe spasticity (spasms, tonic muscle activity and/or clonus) in persons with spinal cord injury (SCI) who are not adequately treated with oral pharmacological management, while avoiding side effects, and also improving voluntary control using surgically implantable targeted tonic spinal cord epidural stimulation (scES). Individuals recruited and enrolled in the study will have significant spasticity not adequately treated by oral medications. Current treatment of severe spasticity by pharmacological treatments are associated with several concomitant side effects that have consequences including limiting the ability to participate in and respond to neurorehabilitation and diminishing quality of life. Also, for persons with SCI and severe spasticity, available rehabilitation therapies are limited in their ability to foster appropriate neural excitation and subsequently motor recovery.

This study focuses on ameliorating severe spasticity through specific spasticity-targeted spinal cord epidural stimulation (SP-scES) that has been shown to mediate levels of neural excitation for movement and unwanted muscle activation. In the long-term, this study will also provide a framework to develop clinically viable approaches with tools to provide optimized care for individuals with chronic SCI. This research is directly aimed to improve the quality of life for those affected by and living with SCI by reducing spasticity (and increasing voluntary control of movement) in the home and community.

Participants will be asked to undergo the research protocol for epidural stimulator surgical implant followed by mapping studies to find the specific stimulation configurations for their spasticity. The intervention portion of the study consists of using the stimulator at home and/or in the training facility and completing assessments. Participants will return for follow-up assessments at 3- and 6-months post-intervention. At the conclusion of the study, participants can choose to have the stimulator removed, turned off, or continue using it at home for spasm management.

02

Conditions studied

  • SCI - Spinal Cord Injury
  • Spasticity
03

In context

Spinal Cord Injuries

1,988 studies on the registry are indexed under Spinal Cord Injuries; 516 are open to participants now.

This study's planned enrollment of 8 is below the median of 24 across 1,594 interventional studies indexed under Spinal Cord Injuries.

Browse Spinal Cord Injuries studies →

Lead sponsor

Kessler Foundation is the lead sponsor of 174 studies on the registry; 60 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 22 years of age
  2. Post 1 year non-progressive SCI
  3. Stable medical condition (cleared by the study physician and do not have any medical conditions that would interfere with study procedures)
  4. Diagnosed with and treated for severe spasticity at least 6 months ago

Exclusion criteria

Exclusion Criteria:

  1. ventilator dependent
  2. untreated painful musculoskeletal dysfunction, fracture or pressure injury
  3. untreated psychiatric disorder or ongoing drug abuse
  4. cardiac, respiratory, bladder, renal or other untreated medical disorder unrelated to SCI
  5. Botulinum toxin injections (such as Botox) or other injections to manage spasms (such as phenol or alcohol) in any muscle or bladder less than 6 months prior to implant
  6. colostomy bag, urostomy
  7. Any active implantable devices or implanted pump (such as a baclofen pump, pain pump, etc.)
  8. pregnant at the time of enrollment or planning to become pregnant during the time course of the study
  9. Contraindications to MRI imaging (e.g., pacemaker, metallic foreign body, aneurysm clip)
  10. Imaging findings that determine the area of spine the stimulation device would be implanted is not suitable for surgery (such as implanted hardware interference or additional deterioration/injury of spinal cord at or below the region)
  11. Severe muscle contractures
  12. unable to operate a touch screen
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Surgically implanted epidural stimulation for spasticity

    Participants will undergo the research protocol for epidural stimulator surgical implant followed by mapping studies to identify targeted stimulation configurations for spasticity. Spinal cord epidural stimulation is administered by a multi-electrode array implanted in the epidural space over the dorsum of the spinal cord.

    Device: Epidural implant stimulation device

Interventions

  • DeviceEpidural implant stimulation device

    Participants will undergo the research protocol for epidural stimulator surgical implant followed by mapping studies to identify targeted stimulation configurations for spasticity.

06

What researchers measure

Primary outcomes

  1. Quantification of muscle Activity Using Integrated EMG in Response to Triggered Spasticity

    Three common triggers of spasticity for each person will be identified, such as quick stretch of the ankle, flexion/extension of the hip, and rapid position changes. Each trigger will be implemented consecutively three times while recording EMG from the hip, knee, and ankle muscles bilaterally. The EMG data will be full wave rectified and filtered using a 4th order bandpass Butterworth filter (40 Hz - 500 Hz) representing the relative number and frequencies of the motor units recruited per burst. Integrated EMG will assess the total EMG activity generated in response to the spasticity trigger for each muscle for each attempt. Muscles: (SOL), medial gastrocnemius (MG), tibialis anterior (TA), medial hamstrings (MH), quadriceps (VL and RF), adductor (AD) and/or other related muscles.

    Time frame: Baseline assessment through study completion, an average of 11 months. Assessments will be performed: prior to being implanted and 3 months and 6 months after implantation, mapping, and device training.

Secondary outcomes

  1. The Penn Spasm Scale

    The Penn Spasm Scale is a 2-part self-report noting both the severity and frequency of spasms. Frequency is a 0-4 scale with 0 being no spasms and 4 being more than 10 spasms per hour. Severity is a 1-3 scale with 1 being mild, 2 is moderate and 3 is severe. Severity is not measured if frequency is 0.

    Time frame: Baseline assessment through study completion, an average of 11 months. Assessments will be performed: prior to being implanted and 3 months and 6 months after implantation, mapping, and device training.

  2. Modified Ashworth Score

    Modified Ashworth Score assesses on a scale of 0 to 4 the resistance of a relaxed, single joint as it is moved throughout its full available range of motion. Participants will be instructed to relax and to allow the examiner to perform the test movement. A zero indicates the area moves freely with no resistance, while a 4 indicates the area is rigid and cannot move.

    Time frame: Baseline assessment through study completion, an average of 11 months. Assessments will be performed: prior to being implanted and 3 months and 6 months after implantation, mapping, and device training.

  3. Frequency of Side Effects

    Participants will report subjective experiences of side effects including fatigue, drowsiness, dizziness, weakness, confusion, headache, nausea, and sexual dysfunction. STIMX PICS algorithms will be recorded using temporaneous recording of each effect and its duration at the time of each experience. STIMX PICS recordings (subjective frequency of side effects) will occur for 24 hours twice prior to implantation and weekly after surgery throughout the 3 months of intervention.

    Time frame: Baseline assessment through study completion, an average of 11 months. Assessments will be performed: prior to being implanted and 3 months and 6 months after implantation, mapping, and device training.

  4. Quantification of Muscle Activity Using Integrated EMG in Response to Voluntary Leg Movement

    Hip and knee extension and flexion and ankle dorsi and plantar flexion will be attempted consecutively three times in response to a 3 tone while recording EMG from the hip, knee, and ankle muscles bilaterally. The EMG data will be full wave rectified and filtered using a 4th order bandpass Butterworth filter (40 Hz - 500 Hz) representing the relative number and frequencies of the motor units recruited per burst.

    Time frame: Baseline assessment through study completion, an average of 11 months. Assessments will be performed: prior to being implanted and 3 months and 6 months after implantation, mapping, and device training.

  5. NeuroRecovery Scale (NRS) for Lower Body and Trunk

    The NRS is a valid, reliable, and responsive evaluation tool for measuring functional recovery in persons with SCI based on tasks that test pre-injury functional capability. It uses a 12-item scale focusing on lower extremity and trunk function including sit up, sit, reverse sit up, trunk extension in sitting, and stand with a maximum score of 72 points, which represents full recovery of pre-injury function, and minimum score of 0 points, which represents no change in functional recovery.

    Time frame: Baseline assessment through study completion, an average of 11 months. Assessments will be performed: prior to being implanted and 3 months and 6 months after implantation, mapping, and device training.

  6. The AIS Impairment Scale

    The ASIA Impairment Scale (AIS) is a classification in SCI that describes the level and severity of the injury, based upon the motor and sensory examination as described in the International Standards of Neurological Classification for SCI (ISNCSCI). This scale ranges from A-E, with A being complete (no motor or sensory function) and E being normal (no sensory or motor impairment)

    Time frame: Baseline assessment through study completion, an average of 11 months. Assessments will be performed: prior to being implanted and 3 months and 6 months after implantation, mapping, and device training.

07

Study locations

1 of 1 sites recruiting
  • Kessler Foundation
    West Orange, New Jersey 07052, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jan 2029, 27 months later.

Of 766 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 27 months is below that.

Counting every sponsor, half of 816 studies reached it within 35 months; a quarter within 16 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 22, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Jan 30, 2029
CompletionEst.
Mar 30, 2029
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07890558
Lead sponsor
Kessler Foundation
Responsible party
Gail Forrest (Director, Tim and Caroline Reynolds Center for Spinal Stimulation, Kessler Foundation) — Principal investigator
First posted
Oct 22, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Jan 30, 2029 (estimated)
Completion
Mar 30, 2029 (estimated)
Last update
Oct 22, 2026

Study contacts

Research Manager
Contact
LMartinez@KesslerFoundation.Org
973-324-3557

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion